PubMed:26483333 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/26483333","sourcedb":"PubMed","sourceid":"26483333","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/26483333","text":"[Clinical Efficacy of Crizotinib in Advanced ALK Positive \u2029Non-small Cell Lung Cancer].\nBACKGROUND: The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.\nMETHODS: patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14). Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily. Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up.\nRESULTS: Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026). The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% (χ2=5.600, P=0.018). Median progression free survival (PFS) of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group (4.0 mo)(P=0.002).\nCONCLUSIONS: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced ALK positive non-small cell lung cancer. The median PFS of patients is shorter. It can improve the quality of life about patients.\u2029.","tracks":[]}